Poor solubility, erratic bioavailability and delivery challenges associated with Glibenclamide, which is commonly used in type 2 diabetes mellitus (T2DM) treatment, are overcome by exploring electrospun nanofibers technology. Employing electrospinning method with polyvinyl alcohol (PVA) combination with poly(D,Llactide-co-glycolic acid) (PLGA), nanofibers were fabricated. Different concentrations of PLGA at 0.02%, 0.03% and 0.05% w/v were added to PVA to achieve a modified drug release profile to meet the typical physiological needs of T2DM, such as a faster drug release at meals followed by prolonged release to maintain constant plasma glucose level, which is highly desirable in T2DM management. Fabricated Glibenclamide-nanofibers were characterized by Scanning electron microscopy (SEM) and Fourier transform infrared (FTIR) spectroscopy. Fabricated nanofibers compressed with other excipients in a tablet and used for oral administration. Formulated tablets were evaluated for hardness, friability, thickness, drug content and in-vitro study. F3 batch was selected as optimize batch from the similarity factor, cumulative drug release and drug content study.